Kidney Medicine

Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark

By Thea K. Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers

Computational studyInterventions

The paper

Thea K. Kjær, Morten Lindhardt, Anders Hammerich Riis, Henrik Birn, Lars Holger Ehlers

Nordic Institute of Health Economics

Kidney Medicine, 12 Aug 2026

doi.org/10.1016/j.xkme.2026.101497 PubMed 42831007

The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes